Chronopharmacokinetics of doxorubicin in patients with breast cancer
The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 1991-01, Vol.40 (3), p.287-291 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 291 |
|---|---|
| container_issue | 3 |
| container_start_page | 287 |
| container_title | European journal of clinical pharmacology |
| container_volume | 40 |
| creator | CANAL, P SQALLI, A DE FORNI, M CHEVREAU, C PUJOL, A BUGAT, R ROCHE, H OUSTRIN, J HOUIN, G |
| description | The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each patient at a four week interval. The total body clearance (CL) of DOX was significantly decreased when the drug was administered at 21.00 h, resulting in a longer elimination half-life and an increase in AUC. The renal clearance of DOX did not differ at the different times of administration, and it appears that the decrease in CL was related to a change in hepatic blood flow. The volume of distribution of the drug was not changed. |
| doi_str_mv | 10.1007/BF00315211 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80647622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80647622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c312t-f1e1af133289148ae5c5fce02eaa49b18f3aff070ab4e925351969434306c1963</originalsourceid><addsrcrecordid>eNpFkEFLxDAQhYMo67p68S70ogehOpOkaXPU1VVhwYueS5pN2GjbrEmL-u_tssWFgRnmfTx4j5BzhBsEyG_vFwAMM4p4QKbIGU0ROB6S6fadCpnDMTmJ8QMAMwlsQiYUBGRCTMnDfB186zdrFRql_adrTed0TLxNVv7Hh75y2rXJMBvVOdN2Mfl23TqpglGxS7RqtQmn5MiqOpqzcc_I--Lxbf6cLl-fXuZ3y1QzpF1q0aCyyBgtJPJCmUxnVhugRikuKywsU9ZCDqriRtKMZSiF5IwzEHo42Yxc7Xw3wX_1JnZl46I2da1a4_tYFiB4LigdwOsdqIOPMRhbboJrVPgtEcptZeW-sgG-GF37qjGrf3TsaNAvR11FrWobhswu7h2lgCIfUv0BEaVyMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80647622</pqid></control><display><type>article</type><title>Chronopharmacokinetics of doxorubicin in patients with breast cancer</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>CANAL, P ; SQALLI, A ; DE FORNI, M ; CHEVREAU, C ; PUJOL, A ; BUGAT, R ; ROCHE, H ; OUSTRIN, J ; HOUIN, G</creator><creatorcontrib>CANAL, P ; SQALLI, A ; DE FORNI, M ; CHEVREAU, C ; PUJOL, A ; BUGAT, R ; ROCHE, H ; OUSTRIN, J ; HOUIN, G</creatorcontrib><description>The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each patient at a four week interval. The total body clearance (CL) of DOX was significantly decreased when the drug was administered at 21.00 h, resulting in a longer elimination half-life and an increase in AUC. The renal clearance of DOX did not differ at the different times of administration, and it appears that the decrease in CL was related to a change in hepatic blood flow. The volume of distribution of the drug was not changed.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00315211</identifier><identifier>PMID: 2060566</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Aged ; Analysis of Variance ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Chemotherapy ; Circadian Rhythm ; Doxorubicin - metabolism ; Doxorubicin - pharmacokinetics ; Female ; Humans ; Kidney - metabolism ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Time Factors</subject><ispartof>European journal of clinical pharmacology, 1991-01, Vol.40 (3), p.287-291</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c312t-f1e1af133289148ae5c5fce02eaa49b18f3aff070ab4e925351969434306c1963</citedby><cites>FETCH-LOGICAL-c312t-f1e1af133289148ae5c5fce02eaa49b18f3aff070ab4e925351969434306c1963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19608713$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2060566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CANAL, P</creatorcontrib><creatorcontrib>SQALLI, A</creatorcontrib><creatorcontrib>DE FORNI, M</creatorcontrib><creatorcontrib>CHEVREAU, C</creatorcontrib><creatorcontrib>PUJOL, A</creatorcontrib><creatorcontrib>BUGAT, R</creatorcontrib><creatorcontrib>ROCHE, H</creatorcontrib><creatorcontrib>OUSTRIN, J</creatorcontrib><creatorcontrib>HOUIN, G</creatorcontrib><title>Chronopharmacokinetics of doxorubicin in patients with breast cancer</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each patient at a four week interval. The total body clearance (CL) of DOX was significantly decreased when the drug was administered at 21.00 h, resulting in a longer elimination half-life and an increase in AUC. The renal clearance of DOX did not differ at the different times of administration, and it appears that the decrease in CL was related to a change in hepatic blood flow. The volume of distribution of the drug was not changed.</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Chemotherapy</subject><subject>Circadian Rhythm</subject><subject>Doxorubicin - metabolism</subject><subject>Doxorubicin - pharmacokinetics</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney - metabolism</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Time Factors</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEFLxDAQhYMo67p68S70ogehOpOkaXPU1VVhwYueS5pN2GjbrEmL-u_tssWFgRnmfTx4j5BzhBsEyG_vFwAMM4p4QKbIGU0ROB6S6fadCpnDMTmJ8QMAMwlsQiYUBGRCTMnDfB186zdrFRql_adrTed0TLxNVv7Hh75y2rXJMBvVOdN2Mfl23TqpglGxS7RqtQmn5MiqOpqzcc_I--Lxbf6cLl-fXuZ3y1QzpF1q0aCyyBgtJPJCmUxnVhugRikuKywsU9ZCDqriRtKMZSiF5IwzEHo42Yxc7Xw3wX_1JnZl46I2da1a4_tYFiB4LigdwOsdqIOPMRhbboJrVPgtEcptZeW-sgG-GF37qjGrf3TsaNAvR11FrWobhswu7h2lgCIfUv0BEaVyMA</recordid><startdate>19910101</startdate><enddate>19910101</enddate><creator>CANAL, P</creator><creator>SQALLI, A</creator><creator>DE FORNI, M</creator><creator>CHEVREAU, C</creator><creator>PUJOL, A</creator><creator>BUGAT, R</creator><creator>ROCHE, H</creator><creator>OUSTRIN, J</creator><creator>HOUIN, G</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19910101</creationdate><title>Chronopharmacokinetics of doxorubicin in patients with breast cancer</title><author>CANAL, P ; SQALLI, A ; DE FORNI, M ; CHEVREAU, C ; PUJOL, A ; BUGAT, R ; ROCHE, H ; OUSTRIN, J ; HOUIN, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c312t-f1e1af133289148ae5c5fce02eaa49b18f3aff070ab4e925351969434306c1963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Chemotherapy</topic><topic>Circadian Rhythm</topic><topic>Doxorubicin - metabolism</topic><topic>Doxorubicin - pharmacokinetics</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney - metabolism</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CANAL, P</creatorcontrib><creatorcontrib>SQALLI, A</creatorcontrib><creatorcontrib>DE FORNI, M</creatorcontrib><creatorcontrib>CHEVREAU, C</creatorcontrib><creatorcontrib>PUJOL, A</creatorcontrib><creatorcontrib>BUGAT, R</creatorcontrib><creatorcontrib>ROCHE, H</creatorcontrib><creatorcontrib>OUSTRIN, J</creatorcontrib><creatorcontrib>HOUIN, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CANAL, P</au><au>SQALLI, A</au><au>DE FORNI, M</au><au>CHEVREAU, C</au><au>PUJOL, A</au><au>BUGAT, R</au><au>ROCHE, H</au><au>OUSTRIN, J</au><au>HOUIN, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronopharmacokinetics of doxorubicin in patients with breast cancer</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1991-01-01</date><risdate>1991</risdate><volume>40</volume><issue>3</issue><spage>287</spage><epage>291</epage><pages>287-291</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each patient at a four week interval. The total body clearance (CL) of DOX was significantly decreased when the drug was administered at 21.00 h, resulting in a longer elimination half-life and an increase in AUC. The renal clearance of DOX did not differ at the different times of administration, and it appears that the decrease in CL was related to a change in hepatic blood flow. The volume of distribution of the drug was not changed.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>2060566</pmid><doi>10.1007/BF00315211</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 1991-01, Vol.40 (3), p.287-291 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80647622 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Analysis of Variance Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Chemotherapy Circadian Rhythm Doxorubicin - metabolism Doxorubicin - pharmacokinetics Female Humans Kidney - metabolism Medical sciences Middle Aged Pharmacology. Drug treatments Time Factors |
| title | Chronopharmacokinetics of doxorubicin in patients with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A08%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronopharmacokinetics%20of%20doxorubicin%20in%20patients%20with%20breast%20cancer&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=CANAL,%20P&rft.date=1991-01-01&rft.volume=40&rft.issue=3&rft.spage=287&rft.epage=291&rft.pages=287-291&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00315211&rft_dat=%3Cproquest_cross%3E80647622%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80647622&rft_id=info:pmid/2060566&rfr_iscdi=true |